TP53 and hepatocellular carcinoma: Lastly, the TP53 pathway analysis showed that TP53 mutations were more common in H/L HCC patients (34.8%) than in NHW patients (27.4%), though this difference was not statistically significant (p = 0.2592, Table S1).